Research Output
Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease
  Alzheimer's disease (AD) is a disorder without a molecular marker in peripheral tissues or a disease modifying treatment. As increasing evidence has suggested a role for glycogen synthase kinase-3 (GSK-3) in the pathogenesis of the condition we measured total GSK-3 protein (alpha and beta isoforms) and GSK-3 activity (serine 9 phosphorylation) in a group of healthy elderly people, in AD and in mild cognitive impairment (MCI). Total GSK-3 protein was increased in both AD and in MCI without a compensatory decrease in activity. These data suggest that GSK-3 assays might be a useful diagnostic marker in a readily available tissue and moreover that GSK-3 activity is increased in the prodromal phase of the disorder suggesting that inhibition of GSK-3 might be a useful therapeutic strategy.

  • Type:

    Article

  • Date:

    11 November 2004

  • Publication Status:

    Published

  • Publisher

    Elsevier BV

  • DOI:

    10.1016/j.neulet.2004.10.031

  • Cross Ref:

    S0304394004012947

  • ISSN:

    0304-3940

  • Library of Congress:

    RC0321 Neuroscience. Biological psychiatry. Neuropsychiatry

  • Dewey Decimal Classification:

    616.8 Nervous & mental disorders

Citation

Hye, A., Kerr, F., Archer, N., Foy, C., Poppe, M., Brown, R., …Lovestone, S. (2004). Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease. Neuroscience Letters, 373(1), 1-4. https://doi.org/10.1016/j.neulet.2004.10.031

Authors

Keywords

Alzheimer's disease; Glycogen synthase kinase-3 (GSK-3); Biomarker; Lymphocytes; White cells; Mild cognitive impairment (MCI)

Monthly Views:

Available Documents